RC
XLO icon

RBF Capital’s Xilio Therapeutics XLO Stock Holding History

RBF Capital’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-719
Closed -$29K – 591
2022
Q3 		$29K Hold
719
– – ﹤0.01% 522
2022
Q2 		$29K Buy
+719
New +$38K ﹤0.01% 521

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

RBF Capital's XLO Position: Q4 2022 in Review

RBF Capital sold out of Xilio Therapeutics (XLO) in Q4 2022, closing a stake of 719 shares — an estimated $29K sold.

RBF Capital first reported a position in XLO in Q2 2022 and held it in 2 quarters. The position peaked at $29K in Q3 2022. 28 funds tracked by Wall St. Rank hold XLO as of Q4 2022.

  • RBF Capital reported no remaining Xilio Therapeutics position as of Q4 2022 after selling out during the quarter.
  • RBF Capital sold 719 Xilio Therapeutics shares in Q4 2022, an estimated $29K.
  • RBF Capital first reported a position in Xilio Therapeutics in Q2 2022 and held it in 2 quarters.
  • RBF Capital's Xilio Therapeutics position peaked at $29K in Q3 2022.
  • 28 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2022.

Based on RBF Capital's 13F filing for Q4 2022, filed 14 Feb 2023.